Commentary
Advertisement
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
When collections waver, a facility’s financial health teeters.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Advocacy for improved reimbursement is crucial to ensuring continued access to care.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Telemedicine has emerged as a game-changer in nephrology.
Building a resilient practice
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
From the Field ...
From the Field ...
From the Field ...
From the Chair ...
From the Field ...
Monogram Health CMO sees many opportunities to improve care for people living with chronic kidney and end-stage renal ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.